Posts tagged TSX-V:DXD
3DS completes assay validation for HL

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) has successfully completed internal analytical assay validation for its Hodgkin's lymphoma (HL) test (Telo-HL) according to FDA guidelines.

Read More
3DS initiates HL validation program

The validation program for 3D Signatures’ (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) Hodgkin's lymphoma test (Telo-HL) is under way. Telo-HL is powered by the company's TeloView software platform.

Read More
3DS to present positive results for prostate cancer liquid biopsy

Dr. Sabine Mai, a co-founder and principle inventor of 3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0), will present on Feb. 21 at the International Molecular Medicine Tri-Conference in San Francisco, results of a prospective blood-based prostate cancer pilot study using the company’s TeloView software platform.

Read More
Prostate cancer study shows benefit of 3DS’ telomere signature analysis

Data from a new study published recently in Urologic Oncology involving men with localized high-risk prostate cancer suggests that the use of 3D Signatures’ (OTCQB:TDSGF; TSX-V:DXD) technology platform, TeloView, may be a promising blood-based treatment-response biomarker in prostate cancer patients who are undergoing combined androgen deprivation therapy (ADT) and radiation therapy (RT).

Read More
3DS begins trading on OTCQB and FSE

Common shares of 3D Signatures (TSX-V:DXD) have started trading on the OTCQB Venture Market in the U.S. under the symbol, TDSGF, and on the Frankfurt Stock Exchange (FSE) in Germany under the symbol, 3D0.

Read More
3DS raises $3.9-million in oversubscribed private placement

3D Signatures (TSX-V:DXD) issued 5,187,618 units under a brokered private placement at a price of 75 cents a unit for gross proceeds of about $3.9-million, including a partial exercise of an over-allotment option.

Read More
3DS names Helen Stevenson to board, Ian Smith to CSAB

3D Signatures (TSX-V:DXD) named Helen Stevenson to the board and Ian Smith, who is stepping down from the board, to the clinical and scientific advisory board (CSAB).

Read More
3DS technology distinguishes between two lung cancers

3D Signatures (TSX-V:DXD) presented preliminary results of a collaborative initiative between the company and the Institut Universitaire de Cardiologie et de Pneumologie De Quebecd, exploring the possibility of identifying a biological marker to distinguish between two deadly forms of lung cancer, multiple synchronous lung adenocarcinoma (AC) and metastatic lung AC, which is a significant unmet clinical need in the management of patients with multiple lung lesions.

Read More
Nigel Terrett joins 3DS business advisory board

3D Signatures (TSX-V:DXD) has appointed Nigel Terrett to 3DS's business advisory board to provide the company with strategic insight and guidance related to commercial lab partnerships and information technology management for its diagnostic platform.

Read More
3D Signatures included in PRECISE prostate cancer trial

3D Signatures (TSX-V:DXD) announced its participation in a major clinical trial for prostate cancer diagnosis and management, known as PRECISE, marking the company's first step toward validation and approval of clinical risk assessment tests for prostate cancer.

PRECISE is led by renowned uro-oncologist and prostate cancer thought leader, Dr. Laurence Klotz, who is chairman of the Canadian Urology Research Consortium, the study sponsor.

Read More
Jason Flowerday named CEO of 3D Signatures

3D Signatures (TSX-V:DXD) has appointed Jason Flowerday as CEO. He succeeds Ferenc Somogyvari, who will remain on the board.

"Mr. Flowerday is a highly respected biotech entrepreneur with more than 20 years of executive life sciences management and startup experience. He has the entrepreneurial and management skills we need to drive us to commercialization," John Swift, chairman, said in a statement.

Read More